Hvivo (HVO) RNS Announcements

Add to Alert list
Date Time Source Announcement
13 Oct 2021 07:00 AM
RNS
Directorate Change
20 Sep 2021 07:00 AM
RNS
Half-year Report
20 Sep 2021 07:00 AM
RNS
£5.7m Influenza human challenge study contract win
09 Sep 2021 07:00 AM
RNS
Notice of Results
07 Sep 2021 07:00 AM
RNS
Positive results from RSV Human Challenge Study
24 Aug 2021 09:05 AM
RNS
Second Price Monitoring Extn
24 Aug 2021 09:00 AM
RNS
Price Monitoring Extension
24 Aug 2021 07:00 AM
RNS
£8.1m Asthma Human Challenge Study Contract Win
09 Aug 2021 07:00 AM
RNS
Malaria Human Challenge Model
29 Jul 2021 07:00 AM
RNS
DNDi Phase II trial support
22 Jul 2021 07:00 AM
RNS
NEJM Opinion Piece
21 Jul 2021 12:58 PM
RNS
Result of AGM
14 Jul 2021 09:06 AM
RNS
Directors' Dealings
14 Jul 2021 08:04 AM
RNS
AIM Schedule 1 update by Poolbeg Pharma plc
14 Jul 2021 07:01 AM
RNS
New Contract win for Open Orphan's Breda office
14 Jul 2021 07:00 AM
RNS
COVID-19 Human Challenge Programme update
09 Jul 2021 07:00 AM
RNS
HRV and Flu contract
07 Jul 2021 04:41 PM
RNS
Second Price Monitoring Extn
07 Jul 2021 04:36 PM
RNS
Price Monitoring Extension
30 Jun 2021 07:00 AM
RNS
2020 Annual Report and 2021 AGM Notice
17 Jun 2021 07:00 AM
RNS
Final Results to 31 December 2020
17 Jun 2021 07:00 AM
RNS
Demerger Update
14 Jun 2021 07:00 AM
RNS
Re. Distribution in Specie and Notice of Results
11 Jun 2021 07:00 AM
RNS
Exercise of Warrants
19 May 2021 07:00 AM
RNS
Court Approval
10 May 2021 07:15 AM
RNS
Exercise of Share Options
10 May 2021 07:00 AM
RNS
£3m COVID challenge virus manufacturing contract
29 Apr 2021 11:39 AM
RNS
Result of General Meeting
13 Apr 2021 07:00 AM
RNS
Potential demerger of certain non-core assets
09 Apr 2021 07:00 AM
RNS
Launch of Disease in Motion platform
31 Mar 2021 07:00 AM
RNS
Holding(s) in Company
26 Mar 2021 07:00 AM
RNS
£7.5m Human Challenge Study Contract
25 Mar 2021 07:00 AM
RNS
COVID-19 Human Challenge Programme update
11 Mar 2021 07:00 AM
RNS
Journal for Clinical Studies article publication
09 Mar 2021 07:00 AM
RNS
New contract win with Oxford BioTherapeutics
26 Feb 2021 04:58 PM
RNS
Holding(s) in Company
17 Feb 2021 09:00 AM
RNS
Ethics approval - COVID-19 Human Challenge Study
09 Feb 2021 03:57 PM
RNS
Holding(s) in Company
03 Feb 2021 07:05 AM
RNS
Exercise of Investor Warrants & TVR
03 Feb 2021 07:00 AM
RNS
New challenge study quarantine clinic
01 Feb 2021 07:00 AM
RNS
Contract extension with Carna Biosciences
21 Jan 2021 07:00 AM
RNS
Article published in Drug Discovery Today
20 Jan 2021 07:00 AM
RNS
Expansion of volunteer recruitment centres
11 Jan 2021 07:00 AM
RNS
First volunteer dosed in COVID-19 clinical trial
06 Jan 2021 04:29 PM
RNS
Holding(s) in Company
06 Jan 2021 07:00 AM
RNS
Contract renewal with top-3 pharmaceutical client
31 Dec 2020 07:00 AM
RNS
Rule 19.6(c) Confirmation
23 Dec 2020 07:00 AM
RNS
Successful completion of toxicology study
22 Dec 2020 07:00 AM
RNS
Contract renewal with top-3 pharmaceutical client
14 Dec 2020 07:30 AM
RNS
Exercise of Share Options

hVIVO is a contract research organization that conducts human challenge clinical trials for respiratory and infectious disease vaccines and therapeutics:

hVIVO offers services such as challenge trials, assay development, field trial bio-logistics, cell based assays, molecular services, compound efficacy and VRM, and biomarker analysis.

Formerly known as Retroscreen, hVIVO was renamed in 2015 when it went public on the London Stock Exchange.

hVIVO has a portfolio of 11 human challenge models, with more models in development. Their portfolio includes models for influenza, respiratory syncytial virus, human rhinovirus, asthma, COPD, cough, malaria, COVID-19, and hMPV.

hVIVO share price launched at 33p in 2012.

UK 100

Latest directors dealings